Hutchmed Initiates P-I Trial of HMPL 295 for the Treatment of Advanced Solid Tumors in China
Shots:
- The company has initiated a P-I open-label study to evaluate the safety- tolerability- PK & preliminary efficacy of HMPL-295 & to determine MTD and RP2D in patients with advanced malignant solid tumors. The 1st patient has been dosed on 02 Jul- 2021
- Following the initial dose-escalation stage- 10 to 15 patients will enroll at RP2D to assess the safety & preliminary efficacy of HMPL-295. Currently- the company retain all rights to HMPL-295 globally
- HMPL-295 is a highly selective ERK inhibitor addressing the RAS-MAPK pathway & has the potential to address intrinsic or acquired resistance from upstream mechanisms. The company plans an exploratory study of HMPL-295 on PK biomarkers
| Ref: PR Newswire | Image: Yahoo Finance
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
